The safety, tolerability, and efficacy of once-daily memantine (28 mg): A multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors

George T. Grossberg*, Facundo Manes, Ricardo F. Allegri, Luis Miguel Gutiérrez-Robledo, Sergio Gloger, Lei Xie, X. Daniel Jia, Vojislav Pejović, Michael L. Miller, James L. Perhach, Stephen M. Graham

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

97 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The safety, tolerability, and efficacy of once-daily memantine (28 mg): A multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors'. Together they form a unique fingerprint.

Medicine & Life Sciences